GlassScriptPhysician profile
Emad U Ahmed
NPI 1144394883
$4,628.85
in general payments reported to CMS, 2019-2025
31 companies · $995 in 2025
The $995 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $432 · 2021: $619 · 2022: $575 · 2023: $624 · 2024: $858 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.28 |
| Education | $278.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $565.60 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $437.27 | 2019-2025 | Farxiga, Lokelma |
| Daiichi Sankyo INC. | $426.14 | 2019-2025 | Injectafer |
| Opko Pharmaceuticals, LLC | $398.90 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $352.12 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $348.88 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $281.60 | 2024-2025 | |
| Travere Therapeutics, INC. | $258.23 | 2019-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $239.42 | 2020-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $205.70 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $156.92 | 2019-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.59 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $108.92 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $107.24 | 2019-2024 | Velphoro |
| Glaxosmithkline, LLC. | $97.01 | 2022-2025 | Benlysta, Arexvy, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $76.87 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $53.46 | 2025 | Ozempic, Rybelsus |
| Amag Pharmaceuticals, INC. | $50.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $44.67 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $39.13 | 2021-2023 | Ultomiris |
| Calliditas Therapeutics US INC. | $35.37 | 2024-2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $35.21 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $28.35 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.37 | 2025 | Empaveli |
| Ardelyx, INC. | $24.09 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $22.79 | 2022 | |
| Scpharmaceuticals INC. | $21.00 | 2023 | |
| Shire North American Group INC | $19.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2025 | Xifaxan |
| Masimo Corporation | $14.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.